A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Thus understanding was gained on the functions and interactions of the proteins employed in the machinery of DNA replication, DNA repair and DNA recombination. Furthermore, understanding was gained on the processes by which viruses are assembled from protein and nucleic acid components (molecular morphogenesis). Also, the role of chain terminating codons was elucidated. One noteworthy study used amber mutants defective in the gene encoding the major head protein of bacteriophage T4. This experiment provided strong evidence for the widely held, but prior to 1964 still unproven, "sequence hypothesis" that the amino acid sequence of a protein is specified by the nucleotide sequence of the gene determining the protein. Thus, this study demonstrated the co-linearity of the gene with its encoded protein. The geographic panorama of the developments of the new biology was conditioned above all by preceding work. The US, where genetics had developed the most rapidly, and the UK, where there was a coexistence of both genetics and biochemical research of highly advanced levels, were in the avant-garde. Germany, the cradle of the revolutions in physics, with the best minds and the most advanced laboratories of genetics in the world, should have had a primary role in the development of molecular biology. But history decided differently: the arrival of the Nazis in 1933—and, to a less extreme degree, the rigidification of totalitarian measures in fascist Italy—caused the emigration of a large number of Jewish and non-Jewish scientists.
== Energy requirements == The energy required to heat water is significantly lower than that needed to vaporize it, for example for steam distillation and the energy is easier to recycle using heat exchangers. The energy requirements can be calculated from steam tables. For example, to heat water from 25 °C to steam at 250 °C at 1 atm requires 2869 kJ/kg. To heat water at 25 °C to liquid water at 250 °C at 5 MPa requires only 976 kJ/kg. It is also possible to recover much of the heat (say 75%) from superheated water, and therefore energy use for superheated water extraction is less than one sixth that needed for steam distillation. This also means that the energy contained in superheated water is insufficient to vaporise the water on decompression. In the above example, only 30% of the water would be converted to vapour on decompression from 5 MPa to atmospheric pressure.
TC# 2.A.3 - Amino Acid-Polyamine-Organocation (APC) Superfamily TC# 2.A.18 - Amino Acid/Auxin Permease (AAAP) Family TC# 2.A.23 - Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family TC# 2.A.26 - Branched Chain Amino Acid:Cation Symporter (LIVCS) Family TC# 2.A.42 - Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family TC# 2.A.78 - Branched Chain Amino Acid Exporter (LIV-E) Family TC# 2.A.95 - 6TMS Neutral Amino Acid Transporter (NAAT) Family TC# 2.A.118 - Basic Amino Acid Antiporter (ArcD) Family TC# 2.A.120 - Putative Amino Acid Permease (PAAP) Family
The mechanism of the flavin reductase process is described above and most likely follows the ping pong kinetic pattern. This means that it is a bisubstrate-biproduct mechanism. First the flavin reductase enzyme binds NADPH and stabilizes the release of the hydride. Because of sterics, it is not possible for the enzyme to bind both NADPH and the flavin. For this reason, NADP+ is released and then the flavin substrate is bound to the enzyme. In this step, the hydride attacks Nitrogen on the flavin, which allows for another protonation. Then, reduced flavin is released from flavin reductase as the second product. In this way, the reduction of flavin is dependent on flavin reductase binding first to NADPH, or in some cases NADH.
unique DNA Also non-repetitive DNA. A class of DNA sequences determined by C0t analysis to be present only once in the analyzed genome, as opposed to repetitive sequences. Most structural genes and their introns are unique.
Sources: en.wikipedia.org
The National Institute for Occupational Safety and Health (NIOSH) is the leading United States federal agency conducting research and providing guidance on the occupational safety and health implications and applications of nanomaterials. Early scientific studies have indicated that nanoscale particles may pose a greater health risk than bulk materials due to a relative increase in surface area per unit mass. Increase in length and diameter of CNT is correlated to increased toxicity and pathological alterations in the lungs. The biological interactions of nanotubes are not well understood, and the field is open to continued toxicological studies. It is often difficult to separate confounding factors, and since carbon is relatively biologically inert, some of the toxicity attributed to carbon nanotubes may be instead due to residual metal catalyst contamination. In previous studies, only Mitsui-7 was reliably demonstrated to be carcinogenic, although for unclear/unknown reasons. Unlike many common mineral fibers (such as asbestos), most SWCNTs and MWCNTs do not fit the size and aspect-ratio criteria to be classified as respirable fibers. In 2013, given that the long-term health effects have not yet been measured, NIOSH published a Current Intelligence Bulletin detailing the potential hazards and recommended exposure limit for carbon nanotubes and fibers. The U.S.
=== 25 July === Russia took the village of Yasnobrodivka in Donetsk Oblast. Russian forces managed to nearly surround two battalions of the Ukrainian 31st Mechanized Brigade near Prohres. Later, according to DeepState, the 31st Mechanized Brigade broke out of the encirclement on the Pokrovsk axis. In Russia, the governor of Belgorod Oblast claimed that one person was killed and two others were injured by Ukrainian shelling in Shebekino. Romanian authorities said that debris from a Russian drone was recovered from the border town of Plauru following an air attack on Izmail. Denmark and the Netherlands pledged to deliver 14 Leopard 2A4 tanks to Ukraine, according to Dutch Defense Minister Ruben Brekelmans. HUR special forces attacked Russian forces at the Kuweires airbase in Syria, destroying an electronic warfare station.
== History == Oxandrolone was first made by Raphael Pappo and Christopher J. Jung while at Searle Laboratories, now part of Pfizer and they first described the drug in 1962. They were immediately interested in oxandrolone's very weak androgenic effects relative to its anabolic effects. It was introduced as a pharmaceutical drug in the United States in 1964. Oxandrolone was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS. It had also been shown to be partially successful in treating cases of osteoporosis. However, in 1989, in part due to bad publicity from its illicit use by bodybuilders, production of Anavar was discontinued by Searle Laboratories. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals. In 1995, following successful clinical trials, Savient released it under the brand name Oxandrin. As of 2011 BTG subsequently had won approvals for orphan drug status by the Food and Drug Administration for treating alcoholic hepatitis, Turner syndrome, and HIV-induced weight loss and as an offset to protein catabolism caused by long-term administration of corticosteroids.
=== Water and Land Management Reforms === Iran’s over-extraction of groundwater and inefficient use of surface water must be addressed. Policies such as water pricing reforms, investment in water-saving technologies, and promoting water recycling could help conserve resources and support agriculture. Combatting soil erosion and desertification through sustainable agricultural practices, such as crop rotation, agroforestry, and organic farming, can enhance food security (Amiraslani & Dragovich, 2011; Emadodin et al., 2012).
Sources: en.wikipedia.org
=== Non-challenge blood glucose tests === When a plasma glucose level is found to be higher than 126 mg/dL (7.0 mmol/L) after fasting, or over 200 mg/dL (11.1 mmol/L) on any occasion, and if this is confirmed on a subsequent day, the diagnosis of GDM is made, and no further testing is required. These tests are typically performed at the first antenatal visit. They are simple to administer and inexpensive, but have a lower test performance compared to the other tests, with moderate sensitivity, low specificity, and high false positive rates.
=== Evolutionary origins === Early humans evolved dark skin color, as an adaptation to a loss of body hair that increased the effects of UV radiation. Before the development of hairlessness, early humans might have had light skin underneath their fur, similar to that found in other primates. Anatomically modern humans evolved in Africa between 200,000 and 100,000 years ago, and then populated the rest of the world through migration between 80,000 and 50,000 years ago, in some areas interbreeding with certain archaic human species (Neanderthals, Denisovans, and possibly others). The first modern humans had darker skin, similar to modern indigenous Africans today. Following migration to Asia and Europe, the selective pressure for darker UV-protective skin decreased. This resulted in the current range of human skin color. Of the two common gene variants known to be associated with pale human skin, Mc1r does not appear to have undergone positive selection, while SLC24A5 has undergone positive selection.
Rhodesian politicians frequently reminded officials in the other two nations of common security interests based on the similarity of their restive internal situations. They saw strong parallels between their nation's position of being threatened by black nationalist insurgencies and the Portuguese predicament with FRELIMO in Mozambique, as well as to a lesser extent the insurgencies in South Africa and South West Africa. Under the auspices of the Alcora Exercise, the three countries' bureaucracies began routinely sharing information and seeking common diplomatic positions. Lieutenant General Alan Fraser, a senior strategist in the South African Defence Force wrote in 1970, "there can be no doubt in any of our minds that we have a common enemy: we, i.e. Portugal, the RSA and Rhodesia. Unless we are to lay ourselves open to the possibility of defeat in detail, we must fight this enemy jointly—if not simultaneously." Nevertheless, aside from intelligence-sharing and some limited coordination on the operational level in Mozambique, the Portuguese could offer Rhodesia little decisive assistance. Portuguese colonial administrators in Mozambique were preoccupied with FRELIMO and somewhat depleted by a decade of war, and little could be spared to assist a foreign ally. Rhodesia expected far more from South Africa, which possessed greater military resources and diplomatic influence abroad at the time. After the Carnation Revolution and the end of Portuguese rule in Mozambique in 1975, it was no longer viable for the Smith regime to sustain white minority rule indefinitely.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.